Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is for the participant to give their own T cells (a type
of blood cell in the body that can fight infections and possibly cancer) to them after they
have been removed, grown in a lab, and then coated with an experimental drug.
This study will determine the highest dose of EGFR2Bi coated T cells that can be given
without causing severe side effects. Initially a group of 3 participants will receive the
same dose of study drug. If no serious side effects occur, the next group of participants
will receive a slightly higher dose of study agent. The following groups of participants will
receive higher doses of the study drug until a dose is reached where there are unacceptable
side effects and maximum tolerated dose is found, or the planned highest dose level is
reached with no side effects.